Gsk Share Discussion Threads

[rikky72] 13/10/2022 22:37

9p? Do you really see that? A valuation of c. £800m? That sounds as nonsensical as saying this will go to £10...

[netcurtains] 13/10/2022 22:03

oh... Well good luck.

[alibizzle] 13/10/2022 21:45

I'm UK . I mean sell my haleon shares when UK stock market opens tomorrow

[netcurtains] 13/10/2022 19:45

Alibizzie: Do you mean you are in the USA?
I'm a bit confused about what your "now" means.

[alibizzle] 13/10/2022 19:19

GSK share price says 1331 here but when I google it it says 1373 ? Also online it says that haleon share price could collapse to 9pence next year so should I sell now ?

[netcurtains] 13/10/2022 16:14

What I like about it is that nearly all other UK stocks have recovered today's small fall but not GSK - HOWEVER, in the USA GSK appears to be doing well.

[tradermichael] 13/10/2022 15:04

There's no better time than now ....

[abdullla] 13/10/2022 15:02

Best Wait for 12 pounds .

[netcurtains] 13/10/2022 14:41

But I'm not going to catch a falling knife until .....

[netcurtains] 13/10/2022 14:41

Would now be a good time to top up? It's tempting.

[rikky72] 13/10/2022 13:54

Perhaps you should encourage George to apply for Emma's job? ;)

[jonjoneil] 13/10/2022 13:43

I think the problem with the good news is that everybody, including Pfizer and my next door neighbor George, is doing late stage trials of an RSV vaccine

[spoole5] 13/10/2022 13:36

Good job there was some good news!

[abdullla] 13/10/2022 12:39

What a crashing day

[abdullla] 13/10/2022 09:16

Sorry Net i am out of fortune cookies today .

[netcurtains] 13/10/2022 09:01

abdullla: do you have a price you think it will be at end of day? You were quite close yesterday. Thanks

[abdullla] 13/10/2022 08:58

What good news and what up and down share price every day!

[netcurtains] 13/10/2022 08:08

MARKET for new Drug:

Respiratory syncytial virus (RSV) infects the lungs and breathing passages, and, in the United States, nearly all children have been infected with RSV by age two. In healthy people, symptoms of RSV infection are usually mild and resolve within a week. However, RSV can cause serious illness or death in vulnerable individuals, including premature and very young infants, children with chronic lung disease or congenital heart disease, and people who are over age 65. In the U.S., RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lungs) in children younger than one year old and causes approximately 58,000 hospitalizations among children under five annually. RSV infection is estimated to cause about 14,000 annual deaths in U.S. adults over age 65. Globally, RSV affects an estimated 64 million people and causes 160,000 deaths each year.

[tradermichael] 13/10/2022 08:01

Yes spyder, truly exceptional results:

GSK's older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial

-- Data to be presented at IDWeek 2022 showed overall vaccine efficacy against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with a favourable safety profile

-- Consistent high vaccine efficacy observed against LRTD in severe disease (94.1%), adults aged 70-79 years (93.8%) and in adults with underlying comorbidities (94.6%)

-- High vaccine efficacy is consistent across RSV A and B strains
GSK plc (LSE/NYSE: GSK) today announced positive pivotal phase III trial results for its respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above to be presented at IDWeek 2022. The vaccine candidate was highly efficacious, demonstrating overall vaccine efficacy of 82.6% (96.95% CI, 57.9-94.1, 7 of 12,466 vs. 40 of 12,494) against RSV lower respiratory tract disease (RSV-LRTD), meeting the trial's primary endpoint.

Consistent high vaccine efficacy was also observed across a range of pre-specified secondary endpoints, highlighting the impact the vaccine candidate could have on the populations most at risk of the severe outcomes of RSV. Efficacy against severe RSV-LRTD, defined as LRTD with at least two lower respiratory signs or assessed as severe by the investigator and confirmed by the external adjudication committee, was 94.1% (95% CI, 62.4-99.9, 1 of 12,466 vs. 17 of 12,494). In participants with pre-existing comorbidities, such as underlying cardiorespiratory and endocrinometabolic conditions, vaccine efficacy was 94.6% (95% CI, 65.9-99.9, 1 of 4,937 vs. 18 of 4,861), with 93.8% (95% CI, 60.2-99.9, 1 of 4,487 vs. 16 of 4,487) efficacy observed in adults aged 70-79 years.

Vaccine efficacy against LRTD was consistent across both RSV-A and RSV-B subtypes (84.6%; CI 32.1-98.3, 2 of 12,466 vs. 13 of 12,494 and 80.9%; CI 49.4-94.3, 5 of 12,466 vs. 26 of 12,494 respectively), consistent with the robust neutralising antibody response generated against both subtypes. See Figure 1: Vaccine efficacy against first episodes of RSV-confirmed LRTD and RSV-confirmed ARI (modified exposed set).

Tony Wood, GSK Chief Scientific Officer, said: "These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research. We believe that with the high vaccine efficacy demonstrated in this pivotal trial, our vaccine candidate has the potential to help reduce the significant global burden of RSV-associated disease in older adults, including those at the greatest risk of severe outcomes due to their age or underlying comorbidities."

The vaccine was well tolerated with a favourable safety profile. The observed solicited adverse events were typically mild-to-moderate and transient, the most frequent being injection site pain, fatigue, myalgia, and headache.

Regulatory submissions based on the phase III data are anticipated in the second half of 2022. GSK's RSV vaccine candidate for older adults contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK's proprietary AS01(E) adjuvant. There are currently no RSV vaccines approved anywhere in the world.

[spyder] 13/10/2022 07:51

Back to fundamentals, excellent results from the RSV vaccine this morning, or in their own words “truly exceptional!”
This is a blockbuster in the making.
We just need to see some positive moves in the Zantac litigation and GSK will be a screaming buy again.

[abdullla] 12/10/2022 17:30

Well it ended the day to almost zero.

[abdullla] 12/10/2022 16:03

Yes Pierre i am not immune,maybe i have'nt a shoulder to cry on .

[pierre oreilly] 12/10/2022 15:51

Abdull, I would think all investors are down loads - are you saying you aren't?

Almost everyone in the uk is down a lot too, only they won't realise it until they cash in their pension/remortgage/try to sell their house.

The only people up are those with luck beyond belief, and a few hundred bankers up billions by either causing or deepening the crisis.

They probably sold in unison everything they had power over at a relatively high pound, and at some stage, they'll buy it all back with low value pounds. Billions upon billions at very little personal risk. Billions into their pockets from those building a pension or otherwise have the city/wall st managing their cash (probably unknowingly).

Not to worry, been through 3 crashes now - it always bounces back and goes higher.

[alibizzle] 12/10/2022 15:30

Yes Abdulla it could be worse but I have no other shares and all my.money with GSK stock